Press release —
Sigrid Therapeutics selected to present results from the STAR Proof of Concept study at the American Diabetes Association's 80th Scientific Conference.
Stockholm, Sweden — June 8, 2020 – Sigrid Therapeutics (Sigrid) announced today that the results from the company’s STAR study have been selected for presentation at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2020. The STAR study (clinicaltrials.org ID number: NCT03823027) was an open-label, single-arm, multicenter study with the primary objective of demonstrating a reduction in long-term blood glucose concentration, measured as HbA1c, in patients with prediabetes after 12 weeks of treatment. The results from the study have the potential to impact the care of patients with prediabetes worldwide. The virtual presentation will be conducted by Sigrid’s senior clinical project manager, Anna Uddén. The results will also be published online on the Diabetes ® journal website.
"We are very pleased to have been selected to present and discuss our latest clinical research findings at the world's largest and most prestigious diabetes meeting. The fact that our data has been selected for presentation reflects the growing interest in our solution among the global diabetes community," says Sigrid's CEO and co-founder, Sana Alajmovic.
The American Diabetes Association 80 th Scientific Sessions
Title: Engineered Silica Particles Reduce HbA1c in Persons with Prediabetes
Date/Time: Saturday, June 13, 2020 10:00 AM US/CENTRAL
Location: Virtual presentation
Presentation number: 1079-P
Topics
Categories
SIGRID is a Swedish consumer health company developing technologies designed to reduce the metabolic impact of modern meals. The company’s patented SiPore® technology works locally in the gastrointestinal tract by interacting with digestive enzymes involved in carbohydrate and fat digestion. By slowing nutrient breakdown during digestion, SiPore® supports steadier post-meal metabolic responses. SIGRID collaborates with clinicians, researchers, and health innovators to translate metabolic science into practical solutions supporting metabolic health, weight management, and glucose stability. The company was founded in 2014 and is headquartered in Stockholm, Sweden.
